Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyDarifenacin
Identification
- Name
- Darifenacin
- Accession Number
- DB00496 (APRD00903)
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Description
Darifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence.
Darifenacin works by blocking the M3 muscarinic acetylcholine receptor, which is primarily responsible for bladder muscle contractions. It thereby decreases the urgency to urinate. It should not be used in people with urinary retention.
It is not known whether this selectivity for the M3 receptor translates into any clinical advantage when treating symptoms of overactive bladder syndrome.
- Structure
Structure for DB00496 (Darifenacin)
- Synonyms
- (S)-1-(2-(2,3-dihydro-5-Benzofuranyl)ethyl)-alpha,alpha-diphenyl-3-pyrrolidineacetamide
- Darifenacin
- Darifenacina
- Darifénacine
- Darifenacinum
- External IDs
- UK 88525 / UK 88525-04
- Product Ingredients
Ingredient UNII CAS InChI Key Darifenacin Hydrobromide CR02EYQ8GV 133099-07-7 UQAVIASOPREUIT-VQIWEWKSSA-N - Product Images
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Darifenacin Tablet, extended release 7.5 mg/1 Oral Actavis Pharma Company 2016-03-15 Not applicable US 
Darifenacin Tablet, extended release 15 mg/1 Oral Actavis Pharma Company 2016-03-15 Not applicable US Enablex Tablet, extended release 15 mg/1 Oral Allergan 2004-12-22 Not applicable US 
Enablex Tablet, extended release 15 mg/1 Oral Lake Erie Medical &Surgical Supply Dba Quality Care Products Llc 2012-03-05 2017-09-22 US Enablex Tablet, extended release 7.5 mg/1 Oral Physicians Total Care, Inc. 2006-11-06 Not applicable US Enablex Tablet, extended release 7.5 mg/1 Oral Allergan 2004-12-22 Not applicable US 
Enablex Tablet, extended release 15 mg Oral Merus Labs Luxco S. A R.L. 2006-04-06 Not applicable Canada 
Enablex Tablet, extended release 15 mg/1 Oral Physicians Total Care, Inc. 2005-07-20 Not applicable US Enablex Tablet, extended release 7.5 mg Oral Merus Labs Luxco S. A R.L. 2006-04-06 Not applicable Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Apo-darifenacin Tablet, extended release 15 mg Oral Apotex Corporation Not applicable Not applicable Canada Apo-darifenacin Tablet, extended release 7.5 mg Oral Apotex Corporation Not applicable Not applicable Canada Darifenacin Tablet, extended release 15 mg/1 Oral Jubilant Cadista Pharmaceuticals Inc. 2016-10-12 Not applicable US Darifenacin Tablet, extended release 15 mg/1 Oral Alembic Pharmaceuticals Limited 2017-12-12 Not applicable US Darifenacin Tablet, extended release 7.5 mg/1 Oral Alembic Pharmaceuticals Limited 2017-12-12 Not applicable US Darifenacin Tablet, extended release 15 mg/1 Oral Cipla Limited 2016-09-01 Not applicable US Darifenacin Tablet, extended release 15 mg/1 Oral Torrent Pharmaceuticals Limited 2016-11-18 Not applicable US Darifenacin Tablet, film coated, extended release 7.5 mg/1 Oral Aurobindo Pharma 2016-09-19 Not applicable US Darifenacin Tablet, extended release 7.5 mg/1 Oral Macleods Pharmaceuticals Limited 2017-07-29 Not applicable US Darifenacin Tablet, extended release 7.5 mg/1 Oral Alembic Pharmaceuticals Limited 2017-12-12 Not applicable US - International/Other Brands
- Emselex (Novartis) / Xelena (Dr. Reddy's)
- Categories
- Anticholinergic Agents
- Cholinergic Agents
- CYP3A Substrates (Sensitive)
- Cytochrome P-450 CYP2D6 Inhibitors
- Cytochrome P-450 CYP2D6 Inhibitors (moderate)
- Cytochrome P-450 CYP3A Substrates
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 CYP3A4 Substrates (strength unknown)
- Cytochrome P-450 Enzyme Inhibitors
- Drugs for Urinary Frequency and Incontinence
- Genito Urinary System and Sex Hormones
- Muscarinic Antagonists
- Neurotransmitter Agents
- Urological Agents
- Urologicals
- UNII
- APG9819VLM
- CAS number
- 133099-04-4
- Weight
- Average: 426.55
Monoisotopic: 426.230728214 - Chemical Formula
- C28H30N2O2
- InChI Key
- HXGBXQDTNZMWGS-RUZDIDTESA-N
- InChI
- InChI=1S/C28H30N2O2/c29-27(31)28(23-7-3-1-4-8-23,24-9-5-2-6-10-24)25-14-17-30(20-25)16-13-21-11-12-26-22(19-21)15-18-32-26/h1-12,19,25H,13-18,20H2,(H2,29,31)/t25-/m1/s1
- IUPAC Name
- 2-[(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide
- SMILES
- NC(=O)C([C@@H]1CCN(CCC2=CC3=C(OCC3)C=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1
Pharmacology
- Indication
For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.
- Associated Conditions
- Pharmacodynamics
Darifenacin is a competitive muscarinic receptor antagonist. In vitro studies using human recombinant muscarinic receptor subtypes show that darifenacin has greater affinity for the M3 receptor than for the other known muscarinic receptors (9 and 12-fold greater affinity for M3 compared to M1 and M5, respectively, and 59-fold greater affinity for M3 compared to both M2 and M4). Muscarinic receptors play an important role in several major cholinergically mediated functions, including contractions of the urinary bladder smooth muscle and stimulation of salivary secretion. Adverse drug effects such as dry mouth, constipation and abnormal vision may be mediated through effects on M3 receptors in these organs.
- Mechanism of action
Darifenacin selectively antagonizes the muscarinic M3 receptor. M3 receptors are involved in contraction of human bladder and gastrointestinal smooth muscle, saliva production, and iris sphincter function.
Target Actions Organism AMuscarinic acetylcholine receptor M3 antagonistHuman UMuscarinic acetylcholine receptor M1 antagonistHuman UMuscarinic acetylcholine receptor M2 antagonistHuman UMuscarinic acetylcholine receptor M4 antagonistHuman UMuscarinic acetylcholine receptor M5 antagonistHuman - Absorption
The mean oral bioavailability at steady state is estimated to be 15% and 19% for 7.5 mg and 15 mg tablets, respectively.
- Volume of distribution
- 163 L
- Protein binding
Darifenacin is approximately 98% bound to plasma proteins (primarily to alpha-1-acid-glycoprotein).
- Metabolism
Hepatic. Primarily mediated by the cytochrome P450 enzymes CYP2D6 and CYP3A4.
- Route of elimination
- Not Available
- Half life
The elimination half-life of darifenacin following chronic dosing is approximately 13-19 hours.
- Clearance
- 40 L/h [extensive metabolizers]
- 32 L/h [poor metabolizers]
- Toxicity
Overdosage can potentially result in severe central anticholinergic effects.
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
Interacting Gene/Enzyme Allele name Genotype(s) Defining Change(s) Type(s) Description Details Cytochrome P450 2D6 CYP2D6*3 Not Available C allele Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*4 Not Available C allele Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*5 Not Available Whole-gene deletion Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*6 Not Available 1707delT Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*7 Not Available 2935A>C Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*8 Not Available 1758G>T Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*11 Not Available 883G>C Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*12 Not Available 124G>A Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*13 Not Available CYP2D7/2D6 hybrid gene structure Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*14A Not Available 1758G>A Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*15 Not Available 137insT, 137_138insT Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*19 Not Available 2539_2542delAACT Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*20 Not Available 1973_1974insG Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*21 Not Available 2573insC Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*31 Not Available -1770G>A / -1584C>G … show all Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*36 Not Available 100C>T / -1426C>T … show all Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*38 Not Available 2587_2590delGACT Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*40 Not Available 1863_1864ins(TTT CGC CCC)2 Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*42 Not Available 3259_3260insGT Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*44 Not Available 2950G>C Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*47 Not Available 100C>T / -1426C>T … show all Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*51 Not Available -1584C>G / -1235A>G … show all Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*56 Not Available 3201C>T Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*57 Not Available 100C>T / 310G>T … show all Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*62 Not Available 4044C>T Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*68A Not Available -1426C>T / -1235A>G … show all Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*68B Not Available Similar but not identical switch region compared to CYP2D6*68A. Found in tandem arrangement with CYP2D6*4. Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*69 Not Available 2988G>A / -1426C>T … show all Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*92 Not Available 1995delC Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*100 Not Available -1426C>T / -1235A>G … show all Effect Inferred Poor drug metabolizer. Details Cytochrome P450 2D6 CYP2D6*101 Not Available -1426C>T / -1235A>G … show all Effect Inferred Poor drug metabolizer. Details Cytochrome P450 3A4 CYP3A4*20 Not Available 1461_1462insA Effect Inferred Poor drug metabolizer. Details Cytochrome P450 3A4 CYP3A4*26 Not Available 802C>T Effect Inferred Poor drug metabolizer. Details
Interactions
- Drug Interactions
Drug Interaction Drug group 1,10-Phenanthroline The therapeutic efficacy of Darifenacin can be decreased when used in combination with 1,10-Phenanthroline. Experimental 4-Methoxyamphetamine The metabolism of 4-Methoxyamphetamine can be decreased when combined with Darifenacin. Experimental, Illicit Abiraterone The serum concentration of Darifenacin can be increased when it is combined with Abiraterone. Approved Acetyl sulfisoxazole The metabolism of Darifenacin can be decreased when combined with Acetyl sulfisoxazole. Approved, Vet Approved Acetylcholine The metabolism of Acetylcholine can be decreased when combined with Darifenacin. Approved Aclidinium Darifenacin may increase the anticholinergic activities of Aclidinium. Approved Agmatine The risk or severity of adverse effects can be increased when Darifenacin is combined with Agmatine. Experimental, Investigational Ajmaline The metabolism of Ajmaline can be decreased when combined with Darifenacin. Approved, Investigational Alcuronium The risk or severity of adverse effects can be increased when Darifenacin is combined with Alcuronium. Experimental Alfentanil The risk or severity of adverse effects can be increased when Darifenacin is combined with Alfentanil. Approved, Illicit Almotriptan The metabolism of Almotriptan can be decreased when combined with Darifenacin. Approved, Investigational Alogliptin The metabolism of Alogliptin can be decreased when combined with Darifenacin. Approved Alphacetylmethadol The risk or severity of adverse effects can be increased when Darifenacin is combined with Alphacetylmethadol. Experimental, Illicit Alphaprodine The risk or severity of adverse effects can be increased when Darifenacin is combined with Alphaprodine. Illicit Alprenolol The metabolism of Alprenolol can be decreased when combined with Darifenacin. Approved, Withdrawn Ambenonium The therapeutic efficacy of Darifenacin can be decreased when used in combination with Ambenonium. Approved Amikacin The therapeutic efficacy of Darifenacin can be decreased when used in combination with Amikacin. Approved, Investigational, Vet Approved Aminophenazone The metabolism of Aminophenazone can be decreased when combined with Darifenacin. Approved, Withdrawn Amiodarone The metabolism of Darifenacin can be decreased when combined with Amiodarone. Approved, Investigational Amitriptyline The metabolism of Amitriptyline can be decreased when combined with Darifenacin. Approved Amoxapine The metabolism of Amoxapine can be decreased when combined with Darifenacin. Approved Amphetamine The metabolism of Amphetamine can be decreased when combined with Darifenacin. Approved, Illicit, Investigational Amprenavir The metabolism of Amprenavir can be decreased when combined with Darifenacin. Approved, Investigational Amsacrine The metabolism of Amsacrine can be decreased when combined with Darifenacin. Approved, Investigational Anisotropine Methylbromide The risk or severity of adverse effects can be increased when Darifenacin is combined with Anisotropine Methylbromide. Approved Antipyrine The metabolism of Antipyrine can be decreased when combined with Darifenacin. Approved, Investigational Apalutamide The serum concentration of Darifenacin can be decreased when it is combined with Apalutamide. Approved, Investigational Aprepitant The serum concentration of Darifenacin can be increased when it is combined with Aprepitant. Approved, Investigational Aprindine The metabolism of Aprindine can be decreased when combined with Darifenacin. Approved Arformoterol The metabolism of Arformoterol can be decreased when combined with Darifenacin. Approved, Investigational Aripiprazole The serum concentration of Aripiprazole can be increased when it is combined with Darifenacin. Approved, Investigational Artemether The metabolism of Artemether can be decreased when combined with Darifenacin. Approved Astemizole The metabolism of Astemizole can be decreased when combined with Darifenacin. Approved, Withdrawn Asunaprevir The metabolism of Asunaprevir can be decreased when combined with Darifenacin. Approved, Investigational, Withdrawn Atazanavir The metabolism of Darifenacin can be decreased when combined with Atazanavir. Approved, Investigational Atomoxetine The metabolism of Darifenacin can be decreased when combined with Atomoxetine. Approved Atracurium The risk or severity of adverse effects can be increased when Darifenacin is combined with Atracurium. Approved, Experimental, Investigational Atracurium besylate The risk or severity of adverse effects can be increased when Darifenacin is combined with Atracurium besylate. Approved Atropine The risk or severity of adverse effects can be increased when Atropine is combined with Darifenacin. Approved, Vet Approved Azelastine The metabolism of Azelastine can be decreased when combined with Darifenacin. Approved Benactyzine The risk or severity of adverse effects can be increased when Darifenacin is combined with Benactyzine. Withdrawn Bendroflumethiazide The serum concentration of Bendroflumethiazide can be increased when it is combined with Darifenacin. Approved Benzatropine The risk or severity of adverse effects can be increased when Benzatropine is combined with Darifenacin. Approved Benzthiazide The serum concentration of Benzthiazide can be increased when it is combined with Darifenacin. Approved Betaxolol The metabolism of Betaxolol can be decreased when combined with Darifenacin. Approved, Investigational Bezitramide The risk or severity of adverse effects can be increased when Darifenacin is combined with Bezitramide. Experimental, Illicit, Withdrawn Biperiden The risk or severity of adverse effects can be increased when Biperiden is combined with Darifenacin. Approved, Investigational Bisacodyl The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Darifenacin. Approved Bisoprolol The metabolism of Bisoprolol can be decreased when combined with Darifenacin. Approved Boceprevir The metabolism of Darifenacin can be decreased when combined with Boceprevir. Approved, Withdrawn Bornaprine The risk or severity of adverse effects can be increased when Bornaprine is combined with Darifenacin. Experimental Bortezomib The metabolism of Darifenacin can be decreased when combined with Bortezomib. Approved, Investigational Bosentan The serum concentration of Darifenacin can be decreased when it is combined with Bosentan. Approved, Investigational Botulinum Toxin Type A Darifenacin may increase the anticholinergic activities of Botulinum Toxin Type A. Approved, Investigational Botulinum Toxin Type B Darifenacin may increase the anticholinergic activities of Botulinum Toxin Type B. Approved, Investigational Brexpiprazole The serum concentration of Brexpiprazole can be increased when it is combined with Darifenacin. Approved, Investigational Brigatinib The serum concentration of Darifenacin can be decreased when it is combined with Brigatinib. Approved, Investigational Brompheniramine The risk or severity of adverse effects can be increased when Darifenacin is combined with Brompheniramine. Approved Bufuralol The metabolism of Bufuralol can be decreased when combined with Darifenacin. Experimental, Investigational Bupivacaine The metabolism of Bupivacaine can be decreased when combined with Darifenacin. Approved, Investigational Buprenorphine The metabolism of Buprenorphine can be decreased when combined with Darifenacin. Approved, Illicit, Investigational, Vet Approved Bupropion The risk or severity of adverse effects can be increased when Darifenacin is combined with Bupropion. Approved Buspirone The metabolism of Buspirone can be decreased when combined with Darifenacin. Approved, Investigational Butorphanol The risk or severity of adverse effects can be increased when Darifenacin is combined with Butorphanol. Approved, Illicit, Vet Approved Butylscopolamine The risk or severity of adverse effects can be increased when Darifenacin is combined with Butylscopolamine. Approved, Investigational, Vet Approved Captopril The metabolism of Captopril can be decreased when combined with Darifenacin. Approved Carbamazepine The metabolism of Darifenacin can be increased when combined with Carbamazepine. Approved, Investigational Carfentanil The risk or severity of adverse effects can be increased when Darifenacin is combined with Carfentanil. Illicit, Investigational, Vet Approved Cariprazine The metabolism of Cariprazine can be decreased when combined with Darifenacin. Approved, Investigational Carteolol The metabolism of Carteolol can be decreased when combined with Darifenacin. Approved Carvedilol The metabolism of Carvedilol can be decreased when combined with Darifenacin. Approved, Investigational Celecoxib The metabolism of Darifenacin can be decreased when combined with Celecoxib. Approved, Investigational Cephalexin The metabolism of Cephalexin can be decreased when combined with Darifenacin. Approved, Investigational, Vet Approved Ceritinib The serum concentration of Darifenacin can be increased when it is combined with Ceritinib. Approved Cevimeline The metabolism of Cevimeline can be decreased when combined with Darifenacin. Approved Chlordiazepoxide The metabolism of Chlordiazepoxide can be decreased when combined with Darifenacin. Approved, Illicit, Investigational Chloroquine The metabolism of Chloroquine can be decreased when combined with Darifenacin. Approved, Investigational, Vet Approved Chlorothiazide The serum concentration of Chlorothiazide can be increased when it is combined with Darifenacin. Approved, Vet Approved Chlorphenoxamine The risk or severity of adverse effects can be increased when Darifenacin is combined with Chlorphenoxamine. Withdrawn Chlorpromazine The metabolism of Darifenacin can be decreased when combined with Chlorpromazine. Approved, Investigational, Vet Approved Chlorthalidone The serum concentration of Chlorthalidone can be increased when it is combined with Darifenacin. Approved Chlorzoxazone The metabolism of Chlorzoxazone can be decreased when combined with Darifenacin. Approved Cholecalciferol The metabolism of Darifenacin can be decreased when combined with Cholecalciferol. Approved, Nutraceutical Cilostazol The metabolism of Cilostazol can be decreased when combined with Darifenacin. Approved, Investigational Cimetropium Darifenacin may increase the anticholinergic activities of Cimetropium. Experimental, Investigational Cinacalcet The metabolism of Darifenacin can be decreased when combined with Cinacalcet. Approved Citalopram The metabolism of Citalopram can be decreased when combined with Darifenacin. Approved Clarithromycin The metabolism of Darifenacin can be decreased when combined with Clarithromycin. Approved Clobazam The metabolism of Darifenacin can be decreased when combined with Clobazam. Approved, Illicit Clomipramine The metabolism of Clomipramine can be decreased when combined with Darifenacin. Approved, Investigational, Vet Approved Clonidine The metabolism of Clonidine can be decreased when combined with Darifenacin. Approved Clotrimazole The metabolism of Darifenacin can be decreased when combined with Clotrimazole. Approved, Vet Approved Clozapine The metabolism of Clozapine can be decreased when combined with Darifenacin. Approved Cobicistat The serum concentration of Darifenacin can be increased when it is combined with Cobicistat. Approved Cocaine The metabolism of Darifenacin can be decreased when combined with Cocaine. Approved, Illicit Codeine The therapeutic efficacy of Codeine can be decreased when used in combination with Darifenacin. Approved, Illicit Conivaptan The serum concentration of Conivaptan can be increased when it is combined with Darifenacin. Approved, Investigational Coumaphos The therapeutic efficacy of Darifenacin can be decreased when used in combination with Coumaphos. Vet Approved Crizotinib The metabolism of Darifenacin can be decreased when combined with Crizotinib. Approved Curcumin The metabolism of Darifenacin can be decreased when combined with Curcumin. Approved, Investigational Cyclobenzaprine The metabolism of Cyclobenzaprine can be decreased when combined with Darifenacin. Approved Cyclopenthiazide The serum concentration of Cyclopenthiazide can be increased when it is combined with Darifenacin. Experimental Cyclopentolate The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Darifenacin. Approved Cyclophosphamide The metabolism of Cyclophosphamide can be decreased when combined with Darifenacin. Approved, Investigational Cyclosporine The metabolism of Darifenacin can be decreased when combined with Cyclosporine. Approved, Investigational, Vet Approved Dabrafenib The serum concentration of Darifenacin can be decreased when it is combined with Dabrafenib. Approved, Investigational Darunavir The serum concentration of Darifenacin can be increased when it is combined with Darunavir. Approved Dasabuvir The metabolism of Dasabuvir can be decreased when combined with Darifenacin. Approved Dasatinib The serum concentration of Darifenacin can be increased when it is combined with Dasatinib. Approved, Investigational Debrisoquin The metabolism of Debrisoquin can be decreased when combined with Darifenacin. Approved, Investigational Decamethonium The therapeutic efficacy of Darifenacin can be decreased when used in combination with Decamethonium. Approved Deferasirox The serum concentration of Darifenacin can be decreased when it is combined with Deferasirox. Approved, Investigational Delavirdine The metabolism of Darifenacin can be decreased when combined with Delavirdine. Approved Demecarium The therapeutic efficacy of Darifenacin can be decreased when used in combination with Demecarium. Approved Desipramine The metabolism of Desipramine can be decreased when combined with Darifenacin. Approved, Investigational Desloratadine The risk or severity of adverse effects can be increased when Darifenacin is combined with Desloratadine. Approved, Investigational Deutetrabenazine The metabolism of Deutetrabenazine can be decreased when combined with Darifenacin. Approved, Investigational Dexamethasone The serum concentration of Darifenacin can be decreased when it is combined with Dexamethasone. Approved, Investigational, Vet Approved Dexchlorpheniramine maleate The metabolism of Dexchlorpheniramine maleate can be decreased when combined with Darifenacin. Approved Dexetimide The risk or severity of adverse effects can be increased when Dexetimide is combined with Darifenacin. Withdrawn Dexfenfluramine The metabolism of Dexfenfluramine can be decreased when combined with Darifenacin. Approved, Illicit, Investigational, Withdrawn Dextroamphetamine The metabolism of Dextroamphetamine can be decreased when combined with Darifenacin. Approved, Illicit Dextromethorphan The risk or severity of adverse effects can be increased when Darifenacin is combined with Dextromethorphan. Approved Dextromoramide The risk or severity of adverse effects can be increased when Darifenacin is combined with Dextromoramide. Experimental, Illicit Dextropropoxyphene The risk or severity of adverse effects can be increased when Darifenacin is combined with Dextropropoxyphene. Approved, Illicit, Investigational, Withdrawn Dezocine The risk or severity of adverse effects can be increased when Darifenacin is combined with Dezocine. Approved, Investigational Dichlorvos The therapeutic efficacy of Darifenacin can be decreased when used in combination with Dichlorvos. Vet Approved Dicyclomine The risk or severity of adverse effects can be increased when Dicyclomine is combined with Darifenacin. Approved Dihydrocodeine The metabolism of Dihydrocodeine can be decreased when combined with Darifenacin. Approved, Illicit Dihydroergotamine The metabolism of Darifenacin can be decreased when combined with Dihydroergotamine. Approved, Investigational Dihydroetorphine The risk or severity of adverse effects can be increased when Darifenacin is combined with Dihydroetorphine. Experimental, Illicit Dihydromorphine The risk or severity of adverse effects can be increased when Darifenacin is combined with Dihydromorphine. Experimental, Illicit Diltiazem The metabolism of Darifenacin can be decreased when combined with Diltiazem. Approved, Investigational Diphenhydramine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Darifenacin. Approved, Investigational Diphenoxylate The risk or severity of adverse effects can be increased when Darifenacin is combined with Diphenoxylate. Approved, Illicit Dipivefrin The therapeutic efficacy of Darifenacin can be decreased when used in combination with Dipivefrin. Approved Distigmine The therapeutic efficacy of Darifenacin can be decreased when used in combination with Distigmine. Experimental Docusate The therapeutic efficacy of Docusate can be decreased when used in combination with Darifenacin. Approved Dolasetron The metabolism of Dolasetron can be decreased when combined with Darifenacin. Approved, Investigational Domperidone The metabolism of Domperidone can be decreased when combined with Darifenacin. Approved, Investigational, Vet Approved Donepezil The therapeutic efficacy of Darifenacin can be decreased when used in combination with Donepezil. Approved Dopamine The metabolism of Dopamine can be decreased when combined with Darifenacin. Approved Dosulepin The metabolism of Darifenacin can be decreased when combined with Dosulepin. Approved Doxepin The metabolism of Doxepin can be decreased when combined with Darifenacin. Approved, Investigational Doxorubicin The serum concentration of Doxorubicin can be increased when it is combined with Darifenacin. Approved, Investigational Doxorubicin The metabolism of Doxorubicin can be decreased when combined with Darifenacin. Approved, Investigational Doxycycline The metabolism of Darifenacin can be decreased when combined with Doxycycline. Approved, Investigational, Vet Approved Doxylamine The risk or severity of adverse effects can be increased when Darifenacin is combined with Doxylamine. Approved, Vet Approved DPDPE The risk or severity of adverse effects can be increased when Darifenacin is combined with DPDPE. Experimental Dronabinol Darifenacin may increase the tachycardic activities of Dronabinol. Approved, Illicit Dronedarone The metabolism of Darifenacin can be decreased when combined with Dronedarone. Approved Duloxetine The metabolism of Darifenacin can be decreased when combined with Duloxetine. Approved Echothiophate The therapeutic efficacy of Darifenacin can be decreased when used in combination with Echothiophate. Approved Edrophonium The therapeutic efficacy of Darifenacin can be decreased when used in combination with Edrophonium. Approved Eletriptan The metabolism of Eletriptan can be decreased when combined with Darifenacin. Approved, Investigational Eliglustat The serum concentration of Eliglustat can be increased when it is combined with Darifenacin. Approved Eluxadoline Darifenacin may increase the constipating activities of Eluxadoline. Approved, Investigational Emepronium The risk or severity of adverse effects can be increased when Darifenacin is combined with Emepronium. Experimental Enasidenib The metabolism of Enasidenib can be decreased when combined with Darifenacin. Approved, Investigational Encainide The metabolism of Encainide can be decreased when combined with Darifenacin. Approved, Investigational, Withdrawn Enclomiphene The metabolism of Enclomiphene can be decreased when combined with Darifenacin. Investigational Enzalutamide The serum concentration of Darifenacin can be decreased when it is combined with Enzalutamide. Approved Epinastine The metabolism of Epinastine can be decreased when combined with Darifenacin. Approved, Investigational Epitizide The serum concentration of Epitizide can be increased when it is combined with Darifenacin. Experimental Erlotinib The metabolism of Erlotinib can be decreased when combined with Darifenacin. Approved, Investigational Erythromycin The metabolism of Darifenacin can be decreased when combined with Erythromycin. Approved, Investigational, Vet Approved Escitalopram The metabolism of Escitalopram can be decreased when combined with Darifenacin. Approved, Investigational Esmirtazapine The metabolism of Esmirtazapine can be decreased when combined with Darifenacin. Investigational Etanautine The risk or severity of adverse effects can be increased when Darifenacin is combined with Etanautine. Experimental Ethopropazine The risk or severity of adverse effects can be increased when Ethopropazine is combined with Darifenacin. Approved Ethylmorphine The metabolism of Ethylmorphine can be decreased when combined with Darifenacin. Approved, Illicit Etoricoxib The metabolism of Etoricoxib can be decreased when combined with Darifenacin. Approved, Investigational Etorphine The risk or severity of adverse effects can be increased when Darifenacin is combined with Etorphine. Illicit, Vet Approved Etybenzatropine The risk or severity of adverse effects can be increased when Darifenacin is combined with Etybenzatropine. Experimental Fentanyl The risk or severity of adverse effects can be increased when Darifenacin is combined with Fentanyl. Approved, Illicit, Investigational, Vet Approved Fenthion The therapeutic efficacy of Darifenacin can be decreased when used in combination with Fenthion. Vet Approved Fesoterodine The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Darifenacin. Approved Fingolimod The metabolism of Fingolimod can be decreased when combined with Darifenacin. Approved, Investigational Flavoxate The risk or severity of adverse effects can be increased when Flavoxate is combined with Darifenacin. Approved Flecainide The metabolism of Flecainide can be decreased when combined with Darifenacin. Approved, Withdrawn Fluconazole The metabolism of Darifenacin can be decreased when combined with Fluconazole. Approved, Investigational Fluoxetine The risk or severity of adverse effects can be increased when Darifenacin is combined with Fluoxetine. Approved, Vet Approved Fluphenazine The metabolism of Fluphenazine can be decreased when combined with Darifenacin. Approved Fluvoxamine The metabolism of Darifenacin can be decreased when combined with Fluvoxamine. Approved, Investigational Formoterol The metabolism of Formoterol can be decreased when combined with Darifenacin. Approved, Investigational Fosamprenavir The metabolism of Darifenacin can be decreased when combined with Fosamprenavir. Approved Fosaprepitant The serum concentration of Darifenacin can be increased when it is combined with Fosaprepitant. Approved Fosphenytoin The metabolism of Darifenacin can be increased when combined with Fosphenytoin. Approved, Investigational Fusidic Acid The serum concentration of Darifenacin can be increased when it is combined with Fusidic Acid. Approved, Investigational Galantamine The therapeutic efficacy of Darifenacin can be decreased when used in combination with Galantamine. Approved Gallamine The risk or severity of adverse effects can be increased when Darifenacin is combined with Gallamine. Experimental Gallamine Triethiodide The risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Darifenacin. Approved Gefitinib The metabolism of Gefitinib can be decreased when combined with Darifenacin. Approved, Investigational Ginkgo biloba The therapeutic efficacy of Darifenacin can be decreased when used in combination with Ginkgo biloba. Approved, Investigational, Nutraceutical Glucagon recombinant The risk or severity of adverse effects can be increased when Darifenacin is combined with Glucagon recombinant. Approved Glycerin The therapeutic efficacy of Glycerin can be decreased when used in combination with Darifenacin. Approved, Investigational Glycopyrronium Darifenacin may increase the anticholinergic activities of Glycopyrronium. Approved, Investigational, Vet Approved Granisetron The metabolism of Granisetron can be decreased when combined with Darifenacin. Approved, Investigational Halofantrine The metabolism of Halofantrine can be decreased when combined with Darifenacin. Approved Haloperidol The metabolism of Haloperidol can be decreased when combined with Darifenacin. Approved Halothane The metabolism of Halothane can be decreased when combined with Darifenacin. Approved, Vet Approved Heroin The risk or severity of adverse effects can be increased when Darifenacin is combined with Heroin. Approved, Illicit, Investigational Homatropine The risk or severity of adverse effects can be increased when Darifenacin is combined with Homatropine. Approved Huperzine A The therapeutic efficacy of Darifenacin can be decreased when used in combination with Huperzine A. Approved, Investigational Hydrochlorothiazide The serum concentration of Hydrochlorothiazide can be increased when it is combined with Darifenacin. Approved, Vet Approved Hydrocodone The serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Darifenacin resulting in a loss in efficacy. Approved, Illicit Hydroflumethiazide The serum concentration of Hydroflumethiazide can be increased when it is combined with Darifenacin. Approved, Investigational Hydromorphone The metabolism of Hydromorphone can be decreased when combined with Darifenacin. Approved, Illicit Hyoscyamine The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Darifenacin. Approved Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Darifenacin. Approved Idarubicin The metabolism of Idarubicin can be decreased when combined with Darifenacin. Approved Idelalisib The serum concentration of Darifenacin can be increased when it is combined with Idelalisib. Approved Iloperidone The metabolism of Iloperidone can be decreased when combined with Darifenacin. Approved Imatinib The metabolism of Darifenacin can be decreased when combined with Imatinib. Approved Imipramine The metabolism of Imipramine can be decreased when combined with Darifenacin. Approved Indapamide The serum concentration of Indapamide can be increased when it is combined with Darifenacin. Approved Indinavir The metabolism of Darifenacin can be decreased when combined with Indinavir. Approved Ipecac The metabolism of Ipecac can be decreased when combined with Darifenacin. Approved, Withdrawn Ipidacrine The therapeutic efficacy of Darifenacin can be decreased when used in combination with Ipidacrine. Experimental Ipratropium The risk or severity of adverse effects can be increased when Darifenacin is combined with Ipratropium. Approved Isavuconazole The serum concentration of Darifenacin can be increased when it is combined with Isavuconazole. Approved, Investigational Isavuconazonium The metabolism of Darifenacin can be decreased when combined with Isavuconazonium. Approved, Investigational Isoflurophate The therapeutic efficacy of Darifenacin can be decreased when used in combination with Isoflurophate. Approved, Investigational, Withdrawn Isoniazid The metabolism of Darifenacin can be decreased when combined with Isoniazid. Approved, Investigational Itopride The therapeutic efficacy of Itopride can be decreased when used in combination with Darifenacin. Investigational Itraconazole The metabolism of Darifenacin can be decreased when combined with Itraconazole. Approved, Investigational Ivacaftor The serum concentration of Darifenacin can be increased when it is combined with Ivacaftor. Approved Ixazomib The metabolism of Ixazomib can be decreased when combined with Darifenacin. Approved, Investigational Ketobemidone The risk or severity of adverse effects can be increased when Darifenacin is combined with Ketobemidone. Approved, Investigational Ketoconazole The metabolism of Darifenacin can be decreased when combined with Ketoconazole. Approved, Investigational Labetalol The metabolism of Labetalol can be decreased when combined with Darifenacin. Approved Lactulose The therapeutic efficacy of Lactulose can be decreased when used in combination with Darifenacin. Approved Lamotrigine The risk or severity of adverse effects can be increased when Darifenacin is combined with Lamotrigine. Approved, Investigational Letermovir The metabolism of Letermovir can be decreased when combined with Darifenacin. Approved, Investigational Levomethadyl Acetate The risk or severity of adverse effects can be increased when Darifenacin is combined with Levomethadyl Acetate. Approved, Investigational Levomilnacipran The metabolism of Levomilnacipran can be decreased when combined with Darifenacin. Approved, Investigational Levorphanol The risk or severity of adverse effects can be increased when Darifenacin is combined with Levorphanol. Approved Lisuride The metabolism of Lisuride can be decreased when combined with Darifenacin. Approved, Investigational Lofentanil The risk or severity of adverse effects can be increased when Darifenacin is combined with Lofentanil. Illicit Lofexidine The metabolism of Lofexidine can be decreased when combined with Darifenacin. Approved, Investigational Lomustine The metabolism of Lomustine can be decreased when combined with Darifenacin. Approved, Investigational Lopinavir The metabolism of Darifenacin can be decreased when combined with Lopinavir. Approved Lorcaserin The metabolism of Lorcaserin can be decreased when combined with Darifenacin. Approved Lorpiprazole The serum concentration of Darifenacin can be increased when it is combined with Lorpiprazole. Approved Lovastatin The metabolism of Darifenacin can be decreased when combined with Lovastatin. Approved, Investigational Luliconazole The serum concentration of Darifenacin can be increased when it is combined with Luliconazole. Approved Lumacaftor The metabolism of Darifenacin can be increased when combined with Lumacaftor. Approved Lumefantrine The metabolism of Darifenacin can be decreased when combined with Lumefantrine. Approved Magnesium carbonate The therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Darifenacin. Approved, Investigational Magnesium citrate The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Darifenacin. Approved Magnesium hydroxide The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Darifenacin. Approved, Investigational Magnesium sulfate The therapeutic efficacy of Magnesium sulfate can be decreased when used in combination with Darifenacin. Approved, Investigational, Vet Approved Malathion The therapeutic efficacy of Darifenacin can be decreased when used in combination with Malathion. Approved, Investigational Maprotiline The metabolism of Maprotiline can be decreased when combined with Darifenacin. Approved, Investigational Mazaticol The risk or severity of adverse effects can be increased when Darifenacin is combined with Mazaticol. Experimental Mecamylamine The risk or severity of adverse effects can be increased when Darifenacin is combined with Mecamylamine. Approved, Investigational Mefloquine The therapeutic efficacy of Darifenacin can be decreased when used in combination with Mefloquine. Approved, Investigational Memantine The therapeutic efficacy of Darifenacin can be decreased when used in combination with Memantine. Approved, Investigational Mephenytoin The metabolism of Mephenytoin can be decreased when combined with Darifenacin. Investigational, Withdrawn Meptazinol The risk or severity of adverse effects can be increased when Darifenacin is combined with Meptazinol. Experimental Mequitazine The metabolism of Mequitazine can be decreased when combined with Darifenacin. Approved Mesoridazine The metabolism of Mesoridazine can be decreased when combined with Darifenacin. Approved, Investigational Methadone The metabolism of Methadone can be decreased when combined with Darifenacin. Approved Methadyl Acetate The risk or severity of adverse effects can be increased when Darifenacin is combined with Methadyl Acetate. Approved, Illicit Methamphetamine The metabolism of Methamphetamine can be decreased when combined with Darifenacin. Approved, Illicit Methanesulfonyl Fluoride The therapeutic efficacy of Darifenacin can be decreased when used in combination with Methanesulfonyl Fluoride. Investigational Methantheline The risk or severity of adverse effects can be increased when Darifenacin is combined with Methantheline. Approved, Investigational Methotrimeprazine The metabolism of Darifenacin can be decreased when combined with Methotrimeprazine. Approved, Investigational Methoxyflurane The metabolism of Methoxyflurane can be decreased when combined with Darifenacin. Approved, Investigational, Vet Approved Methscopolamine The risk or severity of adverse effects can be increased when Darifenacin is combined with Methscopolamine. Approved Methyclothiazide The serum concentration of Methyclothiazide can be increased when it is combined with Darifenacin. Approved Methylscopolamine bromide The risk or severity of adverse effects can be increased when Darifenacin is combined with Methylscopolamine bromide. Approved Methyprylon The metabolism of Methyprylon can be decreased when combined with Darifenacin. Approved, Illicit, Withdrawn Metixene The risk or severity of adverse effects can be increased when Darifenacin is combined with Metixene. Approved Metoclopramide The therapeutic efficacy of Darifenacin can be decreased when used in combination with Metoclopramide. Approved, Investigational Metolazone The serum concentration of Metolazone can be increased when it is combined with Darifenacin. Approved Metoprolol The serum concentration of Metoprolol can be increased when it is combined with Darifenacin. Approved, Investigational Mexiletine The metabolism of Mexiletine can be decreased when combined with Darifenacin. Approved, Investigational Mianserin Mianserin may increase the anticholinergic activities of Darifenacin. Approved, Investigational Mibefradil The metabolism of Darifenacin can be decreased when combined with Mibefradil. Investigational, Withdrawn Miconazole The metabolism of Darifenacin can be decreased when combined with Miconazole. Approved, Investigational, Vet Approved Midostaurin The metabolism of Darifenacin can be decreased when combined with Midostaurin. Approved, Investigational Mifepristone The serum concentration of Darifenacin can be increased when it is combined with Mifepristone. Approved, Investigational Minaprine The therapeutic efficacy of Darifenacin can be decreased when used in combination with Minaprine. Approved Mineral oil The therapeutic efficacy of Mineral oil can be decreased when used in combination with Darifenacin. Approved, Vet Approved Mirabegron The risk or severity of adverse effects can be increased when Darifenacin is combined with Mirabegron. Approved Mirtazapine The metabolism of Mirtazapine can be decreased when combined with Darifenacin. Approved Mitotane The serum concentration of Darifenacin can be decreased when it is combined with Mitotane. Approved Moclobemide The metabolism of Moclobemide can be decreased when combined with Darifenacin. Approved, Investigational Morphine The metabolism of Morphine can be decreased when combined with Darifenacin. Approved, Investigational Nabilone Darifenacin may increase the tachycardic activities of Nabilone. Approved, Investigational Nalbuphine The risk or severity of adverse effects can be increased when Darifenacin is combined with Nalbuphine. Approved Nateglinide The metabolism of Nateglinide can be decreased when combined with Darifenacin. Approved, Investigational Nebivolol The serum concentration of Nebivolol can be increased when it is combined with Darifenacin. Approved, Investigational Nefazodone The metabolism of Darifenacin can be decreased when combined with Nefazodone. Approved, Withdrawn Nelfinavir The metabolism of Darifenacin can be decreased when combined with Nelfinavir. Approved Neomycin The therapeutic efficacy of Darifenacin can be decreased when used in combination with Neomycin. Approved, Vet Approved Neostigmine The therapeutic efficacy of Darifenacin can be decreased when used in combination with Neostigmine. Approved, Vet Approved Netupitant The serum concentration of Darifenacin can be increased when it is combined with Netupitant. Approved, Investigational Nevirapine The metabolism of Darifenacin can be increased when combined with Nevirapine. Approved Nicardipine The risk or severity of adverse effects can be increased when Darifenacin is combined with Nicardipine. Approved, Investigational Nicergoline The metabolism of Nicergoline can be decreased when combined with Darifenacin. Approved, Investigational Nicomorphine The risk or severity of adverse effects can be increased when Darifenacin is combined with Nicomorphine. Experimental Nifedipine The metabolism of Nifedipine can be decreased when combined with Darifenacin. Approved Nilotinib The metabolism of Darifenacin can be decreased when combined with Nilotinib. Approved, Investigational Nitrofural The metabolism of Nitrofural can be decreased when combined with Darifenacin. Approved, Investigational, Vet Approved Normethadone The risk or severity of adverse effects can be increased when Darifenacin is combined with Normethadone. Approved, Illicit Nortriptyline The metabolism of Nortriptyline can be decreased when combined with Darifenacin. Approved Olanzapine The metabolism of Olanzapine can be decreased when combined with Darifenacin. Approved, Investigational Olaparib The metabolism of Darifenacin can be decreased when combined with Olaparib. Approved Ondansetron The metabolism of Ondansetron can be decreased when combined with Darifenacin. Approved Opium The risk or severity of adverse effects can be increased when Darifenacin is combined with Opium. Approved, Illicit Orphenadrine The risk or severity of adverse effects can be increased when Darifenacin is combined with Orphenadrine. Approved Osimertinib The serum concentration of Darifenacin can be increased when it is combined with Osimertinib. Approved Otilonium The risk or severity of adverse effects can be increased when Darifenacin is combined with Otilonium. Experimental, Investigational Oxitropium The risk or severity of adverse effects can be increased when Darifenacin is combined with Oxitropium. Investigational Oxybutynin The risk or severity of adverse effects can be increased when Darifenacin is combined with Oxybutynin. Approved, Investigational Oxycodone The risk or severity of adverse effects can be increased when Darifenacin is combined with Oxycodone. Approved, Illicit, Investigational Oxymorphone The risk or severity of adverse effects can be increased when Darifenacin is combined with Oxymorphone. Approved, Investigational, Vet Approved Oxyphenonium The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Darifenacin. Approved Palbociclib The serum concentration of Darifenacin can be increased when it is combined with Palbociclib. Approved, Investigational Palonosetron The metabolism of Palonosetron can be decreased when combined with Darifenacin. Approved, Investigational Pancuronium The risk or severity of adverse effects can be increased when Darifenacin is combined with Pancuronium. Approved Panobinostat The serum concentration of Darifenacin can be increased when it is combined with Panobinostat. Approved, Investigational Paraoxon The therapeutic efficacy of Darifenacin can be decreased when used in combination with Paraoxon. Experimental Paromomycin The therapeutic efficacy of Darifenacin can be decreased when used in combination with Paromomycin. Approved, Investigational Paroxetine The risk or severity of adverse effects can be increased when Darifenacin is combined with Paroxetine. Approved, Investigational Pazopanib The metabolism of Pazopanib can be decreased when combined with Darifenacin. Approved Peginterferon alfa-2b The serum concentration of Darifenacin can be decreased when it is combined with Peginterferon alfa-2b. Approved Pentamidine The metabolism of Pentamidine can be decreased when combined with Darifenacin. Approved, Investigational Pentazocine The risk or severity of adverse effects can be increased when Darifenacin is combined with Pentazocine. Approved, Vet Approved Pentobarbital The metabolism of Darifenacin can be increased when combined with Pentobarbital. Approved, Investigational, Vet Approved Pentolinium The risk or severity of adverse effects can be increased when Darifenacin is combined with Pentolinium. Approved Perospirone The metabolism of Perospirone can be decreased when combined with Darifenacin. Approved Perphenazine The metabolism of Perphenazine can be decreased when combined with Darifenacin. Approved Pethidine The metabolism of Pethidine can be decreased when combined with Darifenacin. Approved Phenacetin The metabolism of Phenacetin can be decreased when combined with Darifenacin. Withdrawn Phenazocine The risk or severity of adverse effects can be increased when Darifenacin is combined with Phenazocine. Experimental Phenformin The metabolism of Phenformin can be decreased when combined with Darifenacin. Approved, Investigational, Withdrawn Phenglutarimide The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Darifenacin. Experimental Phenobarbital The metabolism of Darifenacin can be increased when combined with Phenobarbital. Approved, Investigational Phenoperidine The risk or severity of adverse effects can be increased when Darifenacin is combined with Phenoperidine. Experimental Phenytoin The metabolism of Darifenacin can be increased when combined with Phenytoin. Approved, Vet Approved Physostigmine The therapeutic efficacy of Darifenacin can be decreased when used in combination with Physostigmine. Approved, Investigational Pindolol The metabolism of Pindolol can be decreased when combined with Darifenacin. Approved, Investigational Pipecuronium The risk or severity of adverse effects can be increased when Darifenacin is combined with Pipecuronium. Approved Piperazine The metabolism of Piperazine can be decreased when combined with Darifenacin. Approved, Vet Approved Pipotiazine The metabolism of Pipotiazine can be decreased when combined with Darifenacin. Approved, Investigational Pirenzepine The risk or severity of adverse effects can be increased when Darifenacin is combined with Pirenzepine. Approved Piritramide The risk or severity of adverse effects can be increased when Darifenacin is combined with Piritramide. Approved, Investigational Pitolisant The serum concentration of Pitolisant can be increased when it is combined with Darifenacin. Approved, Investigational Polythiazide The serum concentration of Polythiazide can be increased when it is combined with Darifenacin. Approved Ponatinib The metabolism of Ponatinib can be decreased when combined with Darifenacin. Approved, Investigational Posaconazole The metabolism of Darifenacin can be decreased when combined with Posaconazole. Approved, Investigational, Vet Approved Potassium Chloride The risk or severity of gastrointestinal ulceration can be increased when Darifenacin is combined with Potassium Chloride. Approved, Withdrawn Pramlintide Pramlintide may increase the anticholinergic activities of Darifenacin. Approved, Investigational Primidone The metabolism of Darifenacin can be increased when combined with Primidone. Approved, Vet Approved Procainamide The metabolism of Procainamide can be decreased when combined with Darifenacin. Approved Procyclidine The risk or severity of adverse effects can be increased when Procyclidine is combined with Darifenacin. Approved Progesterone The metabolism of Progesterone can be decreased when combined with Darifenacin. Approved, Vet Approved Promazine The metabolism of Darifenacin can be decreased when combined with Promazine. Approved, Vet Approved Promethazine The risk or severity of adverse effects can be increased when Darifenacin is combined with Promethazine. Approved, Investigational Propafenone The serum concentration of Darifenacin can be increased when it is combined with Propafenone. Approved Propantheline The risk or severity of adverse effects can be increased when Propantheline is combined with Darifenacin. Approved Propiverine The risk or severity of adverse effects can be increased when Darifenacin is combined with Propiverine. Approved, Investigational Propofol The metabolism of Propofol can be decreased when combined with Darifenacin. Approved, Investigational, Vet Approved Propranolol The metabolism of Propranolol can be decreased when combined with Darifenacin. Approved, Investigational Protriptyline The metabolism of Protriptyline can be decreased when combined with Darifenacin. Approved Pyridostigmine The therapeutic efficacy of Darifenacin can be decreased when used in combination with Pyridostigmine. Approved, Investigational Quetiapine The risk or severity of adverse effects can be increased when Darifenacin is combined with Quetiapine. Approved Quinethazone The serum concentration of Quinethazone can be increased when it is combined with Darifenacin. Approved Quinidine The metabolism of Darifenacin can be decreased when combined with Quinidine. Approved, Investigational Quinine The metabolism of Quinine can be decreased when combined with Darifenacin. Approved Ramosetron Darifenacin may increase the constipating activities of Ramosetron. Approved, Investigational Ranolazine The metabolism of Darifenacin can be decreased when combined with Ranolazine. Approved, Investigational Remifentanil The risk or severity of adverse effects can be increased when Darifenacin is combined with Remifentanil. Approved Remoxipride The metabolism of Remoxipride can be decreased when combined with Darifenacin. Approved, Withdrawn Repinotan The metabolism of Repinotan can be decreased when combined with Darifenacin. Investigational Ribociclib The serum concentration of Darifenacin can be increased when it is combined with Ribociclib. Approved, Investigational Rifabutin The metabolism of Darifenacin can be increased when combined with Rifabutin. Approved, Investigational Rifampicin The metabolism of Darifenacin can be increased when combined with Rifampicin. Approved Rifapentine The metabolism of Darifenacin can be increased when combined with Rifapentine. Approved, Investigational Risperidone The metabolism of Risperidone can be decreased when combined with Darifenacin. Approved, Investigational Ritonavir The metabolism of Darifenacin can be decreased when combined with Ritonavir. Approved, Investigational Rivastigmine The therapeutic efficacy of Darifenacin can be decreased when used in combination with Rivastigmine. Approved, Investigational Rolapitant The metabolism of Darifenacin can be decreased when combined with Rolapitant. Approved, Investigational Ropivacaine The metabolism of Ropivacaine can be decreased when combined with Darifenacin. Approved Rotigotine The metabolism of Rotigotine can be decreased when combined with Darifenacin. Approved Rucaparib The metabolism of Rucaparib can be decreased when combined with Darifenacin. Approved, Investigational Rupatadine The metabolism of Rupatadine can be decreased when combined with Darifenacin. Approved Saquinavir The metabolism of Darifenacin can be decreased when combined with Saquinavir. Approved, Investigational Sarilumab The therapeutic efficacy of Darifenacin can be decreased when used in combination with Sarilumab. Approved, Investigational Scopolamine The risk or severity of adverse effects can be increased when Scopolamine is combined with Darifenacin. Approved, Investigational Secretin human The therapeutic efficacy of Human secretin can be decreased when used in combination with Darifenacin. Approved Sertindole The metabolism of Sertindole can be decreased when combined with Darifenacin. Approved, Investigational, Withdrawn Sertraline The metabolism of Sertraline can be decreased when combined with Darifenacin. Approved Sildenafil The metabolism of Darifenacin can be decreased when combined with Sildenafil. Approved, Investigational Siltuximab The serum concentration of Darifenacin can be decreased when it is combined with Siltuximab. Approved, Investigational Simeprevir The serum concentration of Darifenacin can be increased when it is combined with Simeprevir. Approved Simvastatin The metabolism of Simvastatin can be decreased when combined with Darifenacin. Approved Sodium phosphate, monobasic The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Darifenacin. Approved Solifenacin The risk or severity of adverse effects can be increased when Darifenacin is combined with Solifenacin. Approved Sparteine The metabolism of Sparteine can be decreased when combined with Darifenacin. Experimental St. John's Wort The serum concentration of Darifenacin can be decreased when it is combined with St. John's Wort. Approved, Investigational, Nutraceutical Stiripentol The serum concentration of Darifenacin can be increased when it is combined with Stiripentol. Approved Sufentanil The risk or severity of adverse effects can be increased when Darifenacin is combined with Sufentanil. Approved, Investigational Sulfisoxazole The metabolism of Darifenacin can be decreased when combined with Sulfisoxazole. Approved, Vet Approved Sulpiride Darifenacin may increase the anticholinergic activities of Sulpiride. Approved, Investigational Tacrine The therapeutic efficacy of Darifenacin can be decreased when used in combination with Tacrine. Investigational, Withdrawn Tamoxifen The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Darifenacin resulting in a loss in efficacy. Approved Tamsulosin The metabolism of Tamsulosin can be decreased when combined with Darifenacin. Approved, Investigational Tapentadol The metabolism of Tapentadol can be decreased when combined with Darifenacin. Approved Tegaserod The metabolism of Tegaserod can be decreased when combined with Darifenacin. Approved, Investigational, Withdrawn Telaprevir The metabolism of Darifenacin can be decreased when combined with Telaprevir. Approved, Withdrawn Telithromycin The metabolism of Darifenacin can be decreased when combined with Telithromycin. Approved Terfenadine The metabolism of Terfenadine can be decreased when combined with Darifenacin. Approved, Withdrawn Tesmilifene The metabolism of Tesmilifene can be decreased when combined with Darifenacin. Investigational Tetrabenazine The metabolism of Tetrabenazine can be decreased when combined with Darifenacin. Approved, Investigational Theophylline The metabolism of Theophylline can be decreased when combined with Darifenacin. Approved Thioridazine The serum concentration of Thioridazine can be increased when it is combined with Darifenacin. Approved, Withdrawn Ticlopidine The metabolism of Darifenacin can be decreased when combined with Ticlopidine. Approved Tilidine The risk or severity of adverse effects can be increased when Darifenacin is combined with Tilidine. Experimental Timolol The metabolism of Timolol can be decreased when combined with Darifenacin. Approved Tiotropium Darifenacin may increase the anticholinergic activities of Tiotropium. Approved Tipranavir The metabolism of Darifenacin can be decreased when combined with Tipranavir. Approved, Investigational Tocilizumab The serum concentration of Darifenacin can be decreased when it is combined with Tocilizumab. Approved Tolterodine The risk or severity of adverse effects can be increased when Darifenacin is combined with Tolterodine. Approved, Investigational Topiramate The risk or severity of hyperthermia and oligohydrosis can be increased when Darifenacin is combined with Topiramate. Approved Trabectedin The metabolism of Trabectedin can be decreased when combined with Darifenacin. Approved, Investigational Tramadol The therapeutic efficacy of Tramadol can be decreased when used in combination with Darifenacin. Approved, Investigational Tranylcypromine The metabolism of Darifenacin can be decreased when combined with Tranylcypromine. Approved, Investigational Trazodone The metabolism of Trazodone can be decreased when combined with Darifenacin. Approved, Investigational Trichlorfon The therapeutic efficacy of Darifenacin can be decreased when used in combination with Trichlorfon. Vet Approved Trichlormethiazide The serum concentration of Trichlormethiazide can be increased when it is combined with Darifenacin. Approved, Vet Approved Trihexyphenidyl The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Darifenacin. Approved Trimebutine The risk or severity of adverse effects can be increased when Darifenacin is combined with Trimebutine. Approved Trimethaphan The risk or severity of adverse effects can be increased when Darifenacin is combined with Trimethaphan. Approved, Investigational Trimipramine The metabolism of Trimipramine can be decreased when combined with Darifenacin. Approved Tropatepine The risk or severity of adverse effects can be increased when Darifenacin is combined with Tropatepine. Experimental Tropicamide The risk or severity of adverse effects can be increased when Tropicamide is combined with Darifenacin. Approved, Investigational Trospium The risk or severity of adverse effects can be increased when Trospium is combined with Darifenacin. Approved Tubocurarine The risk or severity of adverse effects can be increased when Darifenacin is combined with Tubocurarine. Approved Tyrothricin The therapeutic efficacy of Darifenacin can be decreased when used in combination with Tyrothricin. Approved Umeclidinium Darifenacin may increase the anticholinergic activities of Umeclidinium. Approved Valbenazine The metabolism of Valbenazine can be decreased when combined with Darifenacin. Approved, Investigational Vecuronium The risk or severity of adverse effects can be increased when Darifenacin is combined with Vecuronium. Approved Vemurafenib The serum concentration of Darifenacin can be decreased when it is combined with Vemurafenib. Approved Venlafaxine The metabolism of Venlafaxine can be decreased when combined with Darifenacin. Approved Verapamil The metabolism of Darifenacin can be decreased when combined with Verapamil. Approved Vernakalant The metabolism of Vernakalant can be decreased when combined with Darifenacin. Approved, Investigational Vilazodone The metabolism of Vilazodone can be decreased when combined with Darifenacin. Approved Vinblastine The metabolism of Vinblastine can be decreased when combined with Darifenacin. Approved Vinorelbine The metabolism of Vinorelbine can be decreased when combined with Darifenacin. Approved, Investigational Voriconazole The metabolism of Darifenacin can be decreased when combined with Voriconazole. Approved, Investigational Vortioxetine The metabolism of Vortioxetine can be decreased when combined with Darifenacin. Approved, Investigational WIN 55212-2 The risk or severity of Tachycardia and drowsiness can be increased when Darifenacin is combined with WIN 55212-2. Experimental Yohimbine The metabolism of Yohimbine can be decreased when combined with Darifenacin. Approved, Investigational, Vet Approved Zalcitabine The metabolism of Zalcitabine can be decreased when combined with Darifenacin. Approved, Investigational Ziprasidone The metabolism of Darifenacin can be decreased when combined with Ziprasidone. Approved Zuclopenthixol The metabolism of Zuclopenthixol can be decreased when combined with Darifenacin. Approved, Investigational - Food Interactions
- Take without regard to meals.
References
- Synthesis Reference
Valeriano Merli, Augusto Canavesi, Paola Daverio, "Processes for preparing darifenacin hydrobromide." U.S. Patent US20070197631, issued August 23, 2007.
US20070197631- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0014639
- KEGG Drug
- D01699
- PubChem Compound
- 444031
- PubChem Substance
- 46508104
- ChemSpider
- 392054
- BindingDB
- 50109647
- ChEBI
- 391960
- ChEMBL
- CHEMBL1346
- Therapeutic Targets Database
- DAP001131
- PharmGKB
- PA164774901
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Darifenacin
- ATC Codes
- G04BD10 — Darifenacin
- AHFS Codes
- 86:12.04 — Antimuscarinics
- FDA label
- Download (394 KB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Novartis pharmaceuticals corp
- Packagers
- Lake Erie Medical and Surgical Supply
- Murfreesboro Pharmaceutical Nursing Supply
- Novartis AG
- Pfizer Inc.
- Physicians Total Care Inc.
- Redpharm Drug
- Dosage forms
Form Route Strength Tablet, film coated, extended release Oral 15 mg/1 Tablet, film coated, extended release Oral 7.5 mg/1 Tablet, extended release Oral 15 mg/1 Tablet, extended release Oral 15 mg Tablet, extended release Oral 7.5 mg/1 Tablet, extended release Oral 7.5 mg - Prices
Unit description Cost Unit Enablex 15 mg 24 Hour tablet 5.22USD tablet Enablex 7.5 mg 24 Hour tablet 5.22USD tablet Enablex 15 mg tablet 5.02USD tablet Enablex 7.5 mg tablet 5.02USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) US5096890 No 1995-03-13 2015-03-13 US CA2469702 No 2010-07-06 2022-03-05 Canada CA2230314 No 2003-06-24 2016-08-21 Canada US6106864 No 1996-08-21 2016-08-21 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source logP 4.5 Not Available - Predicted Properties
Property Value Source Water Solubility 0.000298 mg/mL ALOGPS logP 4.35 ALOGPS logP 4.54 ChemAxon logS -6.2 ALOGPS pKa (Strongest Acidic) 16.21 ChemAxon pKa (Strongest Basic) 10.11 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 55.56 Å2 ChemAxon Rotatable Bond Count 7 ChemAxon Refractivity 128.37 m3·mol-1 ChemAxon Polarizability 48.54 Å3 ChemAxon Number of Rings 5 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9966 Blood Brain Barrier + 0.9989 Caco-2 permeable - 0.5256 P-glycoprotein substrate Substrate 0.6385 P-glycoprotein inhibitor I Non-inhibitor 0.6329 P-glycoprotein inhibitor II Inhibitor 0.5374 Renal organic cation transporter Inhibitor 0.6441 CYP450 2C9 substrate Non-substrate 0.8774 CYP450 2D6 substrate Non-substrate 0.5946 CYP450 3A4 substrate Substrate 0.6046 CYP450 1A2 substrate Non-inhibitor 0.696 CYP450 2C9 inhibitor Non-inhibitor 0.8253 CYP450 2D6 inhibitor Inhibitor 0.5816 CYP450 2C19 inhibitor Inhibitor 0.5399 CYP450 3A4 inhibitor Inhibitor 0.5 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.6168 Ames test Non AMES toxic 0.7145 Carcinogenicity Non-carcinogens 0.8847 Biodegradation Not ready biodegradable 0.9599 Rat acute toxicity 3.0008 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.907 hERG inhibition (predictor II) Inhibitor 0.6703
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Diphenylmethanes
- Direct Parent
- Diphenylmethanes
- Alternative Parents
- Phenylacetamides / Phenethylamines / Coumarans / Aralkylamines / Alkyl aryl ethers / N-alkylpyrrolidines / Trialkylamines / Primary carboxylic acid amides / Amino acids and derivatives / Oxacyclic compounds show 5 more
- Substituents
- Diphenylmethane / Phenylacetamide / Phenethylamine / Coumaran / Alkyl aryl ether / Aralkylamine / N-alkylpyrrolidine / Pyrrolidine / Amino acid or derivatives / Carboxamide group show 18 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- monocarboxylic acid amide, 1-benzofurans, pyrrolidines (CHEBI:391960)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Receptor activity
- Specific Function
- The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
- Gene Name
- CHRM3
- Uniprot ID
- P20309
- Uniprot Name
- Muscarinic acetylcholine receptor M3
- Molecular Weight
- 66127.445 Da
References
- Bharucha AE, Ravi K, Zinsmeister AR: Comparison of selective M3 and nonselective muscarinic receptor antagonists on gastrointestinal transit and bowel habits in humans. Am J Physiol Gastrointest Liver Physiol. 2010 Jul;299(1):G215-9. doi: 10.1152/ajpgi.00072.2010. Epub 2010 Apr 15. [PubMed:20395537]
- Bozkurt TE, Sahin-Erdemli I: M(1) and M(3) muscarinic receptors are involved in the release of urinary bladder-derived relaxant factor. Pharmacol Res. 2009 May;59(5):300-5. doi: 10.1016/j.phrs.2009.01.013. Epub 2009 Feb 5. [PubMed:19416629]
- Jha S, Parsons M: Treatment of overactive bladder in the aging population: focus on darifenacin. Clin Interv Aging. 2006;1(4):309-16. [PubMed:18046909]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Phosphatidylinositol phospholipase c activity
- Specific Function
- The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
- Gene Name
- CHRM1
- Uniprot ID
- P11229
- Uniprot Name
- Muscarinic acetylcholine receptor M1
- Molecular Weight
- 51420.375 Da
References
- Jha S, Parsons M: Treatment of overactive bladder in the aging population: focus on darifenacin. Clin Interv Aging. 2006;1(4):309-16. [PubMed:18046909]
- Moriya H, Takagi Y, Nakanishi T, Hayashi M, Tani T, Hirotsu I: Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. Life Sci. 1999;64(25):2351-8. [PubMed:10374898]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- G-protein coupled acetylcholine receptor activity
- Specific Function
- The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
- Gene Name
- CHRM2
- Uniprot ID
- P08172
- Uniprot Name
- Muscarinic acetylcholine receptor M2
- Molecular Weight
- 51714.605 Da
References
- Jha S, Parsons M: Treatment of overactive bladder in the aging population: focus on darifenacin. Clin Interv Aging. 2006;1(4):309-16. [PubMed:18046909]
- Moriya H, Takagi Y, Nakanishi T, Hayashi M, Tani T, Hirotsu I: Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. Life Sci. 1999;64(25):2351-8. [PubMed:10374898]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Guanyl-nucleotide exchange factor activity
- Specific Function
- The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
- Gene Name
- CHRM4
- Uniprot ID
- P08173
- Uniprot Name
- Muscarinic acetylcholine receptor M4
- Molecular Weight
- 53048.65 Da
References
- Jha S, Parsons M: Treatment of overactive bladder in the aging population: focus on darifenacin. Clin Interv Aging. 2006;1(4):309-16. [PubMed:18046909]
- Moriya H, Takagi Y, Nakanishi T, Hayashi M, Tani T, Hirotsu I: Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. Life Sci. 1999;64(25):2351-8. [PubMed:10374898]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Phosphatidylinositol phospholipase c activity
- Specific Function
- The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
- Gene Name
- CHRM5
- Uniprot ID
- P08912
- Uniprot Name
- Muscarinic acetylcholine receptor M5
- Molecular Weight
- 60073.205 Da
References
- Moriya H, Takagi Y, Nakanishi T, Hayashi M, Tani T, Hirotsu I: Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. Life Sci. 1999;64(25):2351-8. [PubMed:10374898]
- Jha S, Parsons M: Treatment of overactive bladder in the aging population: focus on darifenacin. Clin Interv Aging. 2006;1(4):309-16. [PubMed:18046909]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Skerjanec A: The clinical pharmacokinetics of darifenacin. Clin Pharmacokinet. 2006;45(4):325-50. [PubMed:16584282]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
- Gene Name
- CYP2D6
- Uniprot ID
- P10635
- Uniprot Name
- Cytochrome P450 2D6
- Molecular Weight
- 55768.94 Da
References
- Skerjanec A: The clinical pharmacokinetics of darifenacin. Clin Pharmacokinet. 2006;45(4):325-50. [PubMed:16584282]
Drug created on June 13, 2005 07:24 / Updated on August 14, 2018 07:21